<DOC>
	<DOC>NCT01991301</DOC>
	<brief_summary>The aim of this study is to evaluate the safety and efficacy of Carfilzumib, which is a novel biological agent used in the treatment of multiple myeloma in preventing graft-versus-host disease, after stem cells transplantation from unrelated donors.</brief_summary>
	<brief_title>Carfilzomib for the Prevention of Graft Versus Host Disease</brief_title>
	<detailed_description />
	<mesh_term>Graft vs Host Disease</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>1. Patients with MDS/AML 2. 18 years or older and willing and able to comply with the protocol requirements. 3. LVEF â‰¥ 40%. 2D transthoracic echocardiogram (ECHO) is the preferred method of evaluation. Multigated Acquisition Scan (MUGA) is acceptable if ECHO is not available. 4. Patients undergoing 810/10 HLA matched unrelated and unmanipulated PBSC transplantation 5. Patients conditioned with reduced intensity or reduced toxicity conditioning i.e. Fludarabine combine with Treosulfan or 24 days of I.V Busulfan. 6. Patients must sign written informed consent. 7. Adequate birth control in fertile patients. 1. Patients undergoing other type of transplantation or with other type of basic disease other than AML or MDS. 2. Patients with respiratory failure (DLCO &lt; 30%). 3. Active congestive heart failure (New York Heart Association [NYHA] Class III to IV), symptomatic ischemia, or conduction abnormalities uncontrolled by conventional intervention. 4. Patients with &gt; grade II liver renal toxicity. 5. Psychiatric conditions/disease that impair the ability to give informed consent or to adequately cooperate 6. Bilirubin &gt; 3.0 mg/dl, transaminases &gt; 3 times upper normal limit 7. Creatinine &gt; 2.0 mg/dl 8. ECOGPerformance status &gt; 2 9. Uncontrolled infection 10. Pregnancy or lactation 11. CNS disease involvement 12. Pleural effusion or ascites &gt; 1 liter.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>graft-versus-host disease</keyword>
	<keyword>stem cell transplantation</keyword>
	<keyword>matched unrelated donors</keyword>
	<keyword>proteosmoe inhibitor</keyword>
	<keyword>carfilzumib</keyword>
</DOC>